We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kanabo Group Plc | LSE:KNB | London | Ordinary Share | GB00BYQCS703 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.70 | 1.60 | 1.80 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 603k | -6.87M | -0.0109 | -1.56 | 10.75M |
TIDMKNB
RNS Number : 1660C
Kanabo Group PLC
08 June 2023
8 June 2023
Kanabo Group plc
("Kanabo", the "Group" or the "Company")
Notice of Annual General Meeting
Kanabo Group plc (LSE: KNB), the patient focused healthcare technology and medicinal cannabis company, announces the Notice of Annual General Meeting ("Notice of Meeting") has now been published. The document has been posted to shareholders and is now available to download from the Company's website: https://www.kanabogroup.com/
The Company's Annual General Meeting is scheduled to be help on Friday, 30 June 2023 at Asserson Law Offices of Central Court, 25 Southampton Buildings, Holborn, London WC2A 1AL. The meeting will commence at 1.00 p.m.
The voting results of all resolutions put before the 2023 AGM will be announced shortly afterwards.
Enquiries:
Kanabo Group plc via Vigo Consulting Avihu Tamir, Chief Executive Officer +44 (0)20 7390 0230 Assaf Vardimon, Chief Financial Officer Ian Mattioli, Non-Executive Chair of the Board Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker / Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930 Vigo Consulting (Financial Public Relations/Investor Relations) Jeremy Garcia / Fiona Hetherington / Verity Snow +44 (0)20 7390 kanabo@vigoconsulting.com 0230
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com for more information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAUPUAGQUPWGQR
(END) Dow Jones Newswires
June 08, 2023 12:20 ET (16:20 GMT)
1 Year Kanabo Chart |
1 Month Kanabo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions